



# A Treatment for Iron Overload Diseases by Stabilizing Natural Iron Export


BYU #2017-039

## DESCRIPTION

Researchers at BYU developed a treatment for iron overload diseases. The technology stabilizes natural iron export, allowing the iron to enter the blood stream where the chelator can transport it and excrete it through urine.

## PROBLEM SOLVED

Since humans do not have an iron excretion mechanism, this leads to iron overload in organs, the iron being trapped in the liver, spleen and heart. Most common treatments can be costly and often result in undesired side effects. This technology could potentially replace expensive and unpleasant treatments with it's safer and more effective mode of action. The hepcidin inhibitors prevent hepcidin formation and increase the stability of ferroportin in the cells of the liver and spleen. This enhances iron release from iron-overloaded organs.



## KEY ADVANTAGES

- » Allows for iron release from liver, spleen and heart
- » Enhances the known property of the chelators to excrete the iron

Offer:  
License  
Exclusive  
World Wide  
All Fields of Use

## APPLICATIONS

The invention will be used to treat iron overload diseases - thalassemia and hemochromatosis.

IP STATUS:  
Patent Pending



### Lead Inventor

Dr. Richard Watt  
PhD, Biochemistry



Mike Alder  
mike\_alder@byu.edu  
(801) 422-6266